This week’s theme: This week’s research keeps circling one idea: ADHD’s outcomes hinge on context — gender, caregiving, environment — not the diagnosis alone. The headline event is a landmark new medication approval, wrapped around several studies showing the same label plays out very differently depending on who has it and where they live.

The “ADHD entrepreneur advantage” is mostly a high-IQ-men story; women get the opposite.

Across 4,128 people tracked for 28 years, ADHD alone predicted neither more nor less entrepreneurship; the celebrated advantage only appeared in highly intelligent men, while women with ADHD had the lowest business-ownership rate of any group, regardless of intelligence. The split only surfaces once you account for gender and intelligence.

• Worth knowing because: the same traits sold as a “tailwind” for men can act as a headwind for women, so measuring yourself against that narrative was never a fair test.

Primary: Applied Psychology
Plain-English Read: PsyPost, Aug 1, 2026
Confidence/label: Moderate (large and long-running, but one US observational cohort analyzing occupational choice)

Warm, responsive early caregiving can absorb a prenatal ADHD risk.

Inflammation during pregnancy predicted more ADHD symptoms in kids at age 3, but only where early caregiving was low in sensitivity; where caregiving was attuned, that prenatal risk basically washed out. Think of responsive caregiving (reading and answering a baby's cues) as a shock absorber over a bumpy prenatal road; single observational cohort of 300+ pregnancies.

• Worth knowing because: it frames warm caregiving as a protective lever, not one more thing to master.

• Caution: this is one careless sentence away from mom-blame; the authors explicitly say it isn't prescriptive and no parenting is perfect.

Primary: Journal of Child Psychology & Psychiatry
Plain-English Read: OHSU News, July 31, 2026
Confidence: Watch carefully (underlying evidence is moderate; but framing risk is high)

How stimulant medication actually steadies a child's attention

Using second-by-second brain imaging in 31 children (ages 8–12), a team led by FSU's Tehila Nugiel showed methylphenidate works by calming the flickering — reducing rapid, unstable switching between brain networks so regions communicate more steadily, which tracked with better focus.

• Worth knowing because: It's a satisfying peek under the hood of a decades-old drug, reframing it as a network stabilizer rather than just a stimulant.

Primary: Translational Psychiatry
Plain-English Read: PsyPost, Aug 6, 2026
Confidence/label: Early (small sample, mechanistic)

FDA approves Simtriyo (centanafadine), the first “triple” ADHD drug

The FDA approved Otsuka’s centanafadine (brand name Simtriyo) on July 24 for adults and kids 6+, the first medication that boosts three brain chemicals at once, norepinephrine, dopamine, and serotonin (think of it as widening three lanes of traffic instead of the usual two). But it’s a brand-new commercial launch, so real-world effectiveness and side-effect patterns are still to be seen.

• Worth knowing because: it’s backed by four Phase 3 randomized trials showing symptom improvement as early as week one.

Press Release: Otsuka
Primary: Psychiatric Times
Confidence: Watch carefully

Know someone who needs this? Forward it.

Share

On the horizon

Perimenopause research is heating up and the new ADHD-Her study is recruiting women across the lifespan, estrogen’s role in ADHD symptoms is shaping up to be a story to follow.
Study details: CADDRA

Scope note

All items were checked against their reporting source and, where reachable, the underlying journal. Screening tools and cross-sectional designs are flagged because they show associations, not proof of cause. This briefing is informational and not medical advice.

On confidence

Strong = meta-analysis, large longitudinal study, or replicated finding;
Moderate = solid but narrower or observational;
Early = new, small, or preliminary;
Watch carefully = controversial, pregnancy- or treatment-adjacent, or commercially promoted. Each item carries one label.

➤ Browse every briefing

Keep reading

Further reading:
ADHD & Sleep | Research Briefing

Connect:
About Me | Bluesky | 🥤 Buy Me A Coffee | Facebook | Instagram | YouTube

The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.

This week’s theme: Women and girls dominated the ADHD conversation, and the field got its first genuinely new medication mechanism in years. Little brand-new peer-reviewed science dropped in the last 7 days, so I’ve led with the two solid this-week items and rounded out with clearly-dated context.

The FDA approved a new-mechanism ADHD drug

The FDA approved centanafadine (brand name Simtriyo) on July 24, a once-daily pill that’s the first of its kind for ADHD. Think of most ADHD meds as turning up two brain signals; this one turns up three (norepinephrine, dopamine, and serotonin), which could help people who don’t tolerate or respond to stimulants. It’s backed by four Phase 3 trials in kids, teens, and adults showing real symptom gains.

• Worth knowing because: it’s a freshly launched, heavily marketed drug and the full trial data haven’t been published yet, so temper the hype until the numbers are public.

Primary: Psychiatric Times
Confidence: Watch carefully

Missed ADHD in women carries a steep, hidden health cost

A widely-shared NPR feature pulled together why ADHD in girls slips under the radar: girls tend to look "spacey" rather than disruptive, so they're diagnosed years later than boys, often not until adulthood, after years of being treated for anxiety or depression instead. The stakes are high: a large UK registry study found women with ADHD die on average nearly nine years earlier than peers without it, with elevated rates of obesity, eating disorders, type 2 diabetes, and heart disease.

• Worth knowing because: this is the clearest evidence yet that the delay was a system failure.

Primary: The British Journal of Psychiatry, Jan 2025, original mortality study
Plain-English read: NPR, Living Better Series
Confidence: Strong (large matched cohort, ~30,000 adults with ADHD vs 300,000 matched controls)

Not New, Still Relevant

Girls out-diagnosed boys for the first time in a large dataset

Analyzing health records for 2.7 million people in British Columbia, researchers found that after the pandemic, ADHD diagnoses in teen girls and young women passed boys for the first time on record. It's one region's data, so it reflects a diagnosis pattern rather than a true prevalence flip — but it's concrete evidence that the historic "ADHD is a boy thing" gap is closing fast.

• Worth knowing because: the wave of late-diagnosed women isn't an anomaly, it's a correction now visible in the data.

Primary: JAMA Network Open
Plain-English read: CHADD, April 8, 2026
Confidence: Moderate (observational)

Midlife isn't new fragility, it's a missing backup

Women with ADHD report more severe perimenopausal symptoms than women without it, and midlife is when many get diagnosed for the first time. When estrogen drops, it pulls dopamine support down with it, so the coping scaffolding that held for decades stops holding. Think losing the guardrails on a road you've driven safely for years.

• Worth knowing because: the midlife "falling apart" isn't new fragility, it's an old system losing its hormonal backup.

Primary: European Psychiatry
Confidence: Moderate (population-based cohort, observational)

Know someone who needs this? Forward it.

Share

On the horizon

Otsuka says full centanafadine trial results are coming at an upcoming scientific meeting, that’s when we’ll see how the new drug actually stacks up against stimulants.

Also tracking the hormone thread: with perimenopause research heating up and the new ADHD-Her study recruiting women across the lifespan, estrogen’s role in ADHD symptoms is shaping up to be a story to follow.
Study details: CADDRA

Scope note

All items were checked against their reporting source and, where reachable, the underlying journal. Screening tools and cross-sectional designs are flagged because they show associations, not proof of cause. This briefing is informational and not medical advice.

On confidence

Strong = meta-analysis, large longitudinal study, or replicated finding;
Moderate = solid but narrower or observational;
Early = new, small, or preliminary;
Watch carefully = controversial, pregnancy- or treatment-adjacent, or commercially promoted. Each item carries one label.

➤ Browse every briefing

Keep reading

Further reading:
ADHD & Sleep | Research Briefing

Connect:
About Me | Bluesky | 🥤 Buy Me A Coffee | Facebook | Instagram | YouTube

The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.

This week’s theme: The research spotlight landed on everyday life — sleep, screens, and how people actually use their meds — rather than on brain wiring. Think of it as studying the weather ADHD lives in, not the climate it's born with. Plus, new drug: centanafadine is on the horizon.

When emotions are hard to manage, sleep pays the price (a mostly-female sample)

In a study of 1,414 adults with ADHD — 81% of them women — the people who struggled most to steer their emotions were the ones most likely to report insomnia. Emotional distress keeps the body in hyperarousal at bedtime, so the shutdown signal never fires. Being a night owl did not explain it, and neither did depression or medication status. Picture a car with no brakes: feelings keep rolling at night and won’t let the mind park.

• Worth knowing because: it points to emotional coping as a lever worth pulling when someone with ADHD can’t sleep, especially younger adults and women, who are underrepresented in most ADHD research.

Primary: Journal of Affective Disorders
Plain-English read: Adults with ADHD who struggle to manage emotions face a higher insomnia risk
Confidence: Moderate (cross-sectional, self-report, self-reported diagnosis)
Further Reading: ADHD & Sleep

Girls may have been missed again — because parents were doing the rating

Across 11,286 adolescents followed five years in the ABCD study, a rise in addictive-quality use at 14 or 15 predicted more parent-reported ADHD symptoms a year later. The reverse pattern was much weaker and inconsistent: higher ADHD symptoms did not reliably predict more addictive-quality social media use the following year. What mattered was the loss of control, not hours logged.

• Worth knowing because: ADHD symptoms here were rated by parents, and parents are the exact group that has historically missed ADHD in daughters, so "no effect in girls" and "nobody saw it in girls" are not distinguishable in this design.

Primary: JAMA Network, July 2026
Plain English version: Washington Post
Confidence: Strong (large longitudinal cohort, within-person modeling, but observational)

Misuse of ADHD stimulants among adults under 30 fell by half, from 7.5% in 2016 to 3.7% in 2023.

First mention: ADHD Research Briefing: Week of July 10–17, 2026

A rapid review of 64 studies found misuse of ADHD stimulants like Adderall roughly halved among adults under 30 — from about 7.5% in 2016 to 3.7% in 2023 — and has held steady since. Part of the drop likely traces to the 2022 shortage, when nearly 72% of patients struggled to fill a prescription, which is a bleak way to earn a good statistic.

• Worth knowing because: Encouragingly, the same review found no sign that taking prescribed ADHD medication as a teen raises the risk of later substance abuse.

Primary: Journal of Clinical Psychopharmacology
Press Release: Keck School of Medicine of USC, July 9, 2026
Confidence: Moderate

Know someone who needs this? Forward it.

Share

On the horizon

The FDA's decision deadline on centanafadine, a first-in-class non-stimulant, is today, July 24, 2026.

Centanafadine, an experimental non-stimulant that nudges three brain chemicals at once (norepinephrine, dopamine, serotonin), is up for an FDA decision on July 24, 2026. New follow-up analyses of its Phase 3 trials in ~744 adults suggest it helps not just core symptoms but also executive function — think time management, planning, starting and finishing tasks — plus emotional regulation.

• Read with caution: these are post-hoc looks (analyses run after the fact), not the trial’s main scorecard, and they come from the drug’s maker.

Primary: Psychiatric Times

Scope note

All items were checked against their reporting source and, where reachable, the underlying journal. Screening tools and cross-sectional designs are flagged because they show associations, not proof of cause. This briefing is informational and not medical advice.

On confidence

Strong = meta-analysis, large longitudinal study, or replicated finding;
Moderate = solid but narrower or observational;
Early = new, small, or preliminary;
Watch carefully = controversial, pregnancy- or treatment-adjacent, or commercially promoted. Each item carries one label.

➤ Browse every briefing

Keep reading

Further reading:
ADHD & Sleep | Research Briefing

Connect:
About Me | Bluesky | 🥤 Buy Me A Coffee | Facebook | Instagram | YouTube

The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.

This week's theme: The freshest, most solid news is a set of treatment reality-checks — one thing that clearly doesn't work, one new drug at the FDA's door, and a big pregnancy-safety reversal — while genuinely new research focused specifically on women and girls was thin this week (the strongest women-and-girls item is a few weeks old and flagged as such below).

Stimulant misuse among U.S. adults is dropping — but a shortage may be why

A rapid review of 64 studies found misuse of ADHD stimulants like Adderall roughly halved among adults under 30 — from about 7.5% in 2016 to 3.7% in 2023 — and has held steady since. The catch: the drop lines up with the national stimulant shortage that started in 2022, when most patients struggled to fill prescriptions, so “less misuse” may partly reflect “less available.”

• Worth knowing because: Encouragingly, the same review found no sign that taking prescribed ADHD medication as a teen raises the risk of later substance abuse.

Primary: Journal of Clinical Psychopharmacology
Press Release: Keck School of Medicine of USC, July 9, 2026
Confidence: Moderate

Brain-zapping gadgets don’t move the needle on ADHD

Pooling seven trials of about 300 people, researchers found that tDCS — a wearable device that runs a gentle electrical current across the forehead to “wake up” the brain’s control center — did no better than a fake, switched-off version. Neither focus, hyperactivity, working memory, nor impulse control improved.

• Worth knowing because: these devices are marketed to families as a drug-free fix, and this is the clearest signal yet that, for now, the science isn’t there.

Primary: Frontiers in Psychiatry
Plain-English read: The ADHD Evidence Project, July 2, 2026
Confidence: Strong

ADHD and autism may leave opposite “fingerprints” in the immune system

A new analysis reports that autism tends to come with elevated inflammatory signals in the blood, while ADHD tends to come with lower ones — like two conditions leaving mirror-image marks.

• Worth knowing because: If it holds up, it hints that these overlapping diagnoses may have genuinely different biology under the hood. It’s early and preliminary, though — a pattern to file away, not a test you’ll see at the doctor’s office anytime soon.

Primary: European Child Adolescent Psychiatry (2026)
Plain-English read: Psychiatry Advisor
Confidence: Early

Not New, Still Relevant

Girls with childhood ADHD carry a heavier adult health load — poverty piles it on

Published ~May 2026

Following a large group of women born in Wales and tracking their health records into their early 30s, researchers found girls diagnosed with ADHD in childhood were more than twice as likely to develop several long-term health conditions at once as adults. When childhood poverty was also in the picture, the two stacked like weights on the same scale — roughly 39% of the extra health burden came from ADHD and deprivation combined.

• Worth knowing because: It’s a reminder that ADHD in girls is a whole-body, whole-life issue, not just a school-years attention problem.

Primary: Nature Mental Health
Plain-English Read: Medical Express
Confidence: Strong

Know someone who needs this? Forward it.

Share

On the horizon

A new non-stimulant heads to the FDA — decision due July 24

Centanafadine, an experimental non-stimulant that nudges three brain chemicals at once (norepinephrine, dopamine, serotonin), is up for an FDA decision on July 24, 2026. New follow-up analyses of its Phase 3 trials in ~744 adults suggest it helps not just core symptoms but also executive function — think time management, planning, starting and finishing tasks — plus emotional regulation.

• Read with caution: these are post-hoc looks (analyses run after the fact), not the trial’s main scorecard, and they come from the drug’s maker.

Primary: Psychiatric Times

Scope note

This was a quiet week for brand-new peer-reviewed research on ADHD in women and girls specifically. Rather than pad the list, the briefing surfaces the most substantive verified items available and flags the one older-but-important women-and-girls study.

On confidence

Strong = meta-analysis, large longitudinal study, or replicated finding;
Moderate = solid but narrower or observational;
Early = new, small, or preliminary;
Watch carefully = controversial, pregnancy- or treatment-adjacent, or commercially promoted. Each item carries one label.

Keep reading

• Browse every briefing

Further reading:
ADHD & Sleep | Research Briefing

Connect:
About Me | Bluesky | Facebook | Instagram | Pinterest | YouTube

The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.

The theme this week: Researchers are questioning the boxes. The standout new paper argues ADHD isn't a tidy category at all: it blurs into autism and learning differences along one shared spectrum. Meanwhile, women's-health and pregnancy findings keep reshaping who gets diagnosed and how they're safely treated.

ADHD, autism, and learning differences may sit on one shared spectrum, not in three separate boxes

Using data on more than 10,000 children from the UK’s Twins Early Development Study (tracked at ages 7, 12, and 16), researchers found that traits of ADHD, autism, and learning and language difficulties (including reading, so dyslexia-type traits) load onto a single underlying “neurodevelopmental spectrum” that is strongly inherited, with heritability rising across childhood from roughly 60% to 82%. Picture it less as three separate rooms and more as colors bleeding into one another on a single strip.

• Worth knowing because: it supports assessing a child’s whole constellation of traits rather than chasing one diagnostic label, which could help the many kids, and adults, who never fit neatly in one box.

Study: Large sibling study, peer-reviewed
Read it: Molecular Psychiatry (Michelini et al., Jul 2026)
Plain English: Medical Xpress summary

Girls with childhood ADHD carry heavier adult health burdens, and poverty compounds it

A large population study following women born in Wales between 1991 and 1998 through linked health records, found that girls diagnosed with ADHD in childhood were significantly more likely to develop multiple long-term health conditions by early adulthood. When childhood socioeconomic deprivation was also present, the risk more than doubled, and nearly 39% of the excess health burden came from ADHD and deprivation acting together, a one-two punch rather than two separate hits. The most severe pattern, which researchers called “pan-system” multimorbidity, combined physical conditions with complex mental-health diagnoses.

• Worth knowing because: it reframes childhood ADHD in girls as an early-warning flag for lifelong physical health, not just a school-years attention issue.

Study: Large population cohort, peer-reviewed
Primary: Nature Mental Health (Wilson et al., 2026)
Press Release: University of Glasgow

ADHD medication in pregnancy and preterm birth: dose seems to matter

This study found early-pregnancy ADHD medication linked to higher preterm-birth risk only with two or more filled prescriptions (about 29% higher), not with a single fill, and in late pregnancy the risk rose with each additional 30 days of cumulative exposure. Context matters: other 2026 reviews find that continuing medication is often safer than stopping, so this is one signal in a mixed, still-forming picture.

• Worth knowing because: it gives pregnant patients and clinicians more concrete numbers for a hard risk-benefit conversation, not a reason to stop cold.

Study: Large population cohort, peer-reviewed
Primary: Paediatric and Perinatal Epidemiology (Srinivas, 2026) |
Plain English: free abstract on PubMed (no dedicated lay writeup yet)

Psychedelics for ADHD: “not ready,” scientists caution

Still not ready. The psychedelics-for-ADHD caution we covered last week holds, and this week's coverage is a re-push of the same review, no new data.

A Polish team (Wroclaw Medical University) found only five usable studies on psychedelics for adult ADHD, all small, with different substances, doses, and short follow-ups. The one randomized placebo-controlled trial showed improvement in both the LSD and placebo groups, with no significant edge for LSD. The verdict: the evidence is not there yet to call it a treatment.

• Worth knowing because: microdosing is heavily hyped online, and this is a sober reminder that hype is running well ahead of the data.

Study: Early-stage review, limited studies
Primary: International Journal of Molecular Sciences, April 2026
Plain English: Wroclaw Medical University

ICYMI

Perimenopause hits women with ADHD harder, and earlier

Originally published: September 2025

Iceland's SAGA study (5,392 women, ages 35 to 55) found women with ADHD reported more severe perimenopausal symptoms that began earlier than in women without ADHD. As estrogen and progesterone swing, ADHD traits like fog, impulsivity, and emotional overwhelm tend to flare, like a radio losing signal when the tuning drifts.

• Worth knowing because: midlife is when many women are finally diagnosed, and this points to hormones as a real, and potentially treatable, amplifier rather than “just stress.”

Study: Population cohort study, peer-reviewed
Primary: European Psychiatry (Sept 2025), full text: PubMed
Plain English: ADDitude coverage

On the horizon

The FDA’s decision on centanafadine, a first-in-class non-stimulant (a norepinephrine, dopamine, and serotonin reuptake inhibitor), is due July 24, 2026. Otsuka reported positive Phase 3b results (June 25) in adults with ADHD and co-occurring anxiety, a group current meds often struggle with. With a commercial launch approaching, watch the marketing as closely as the data.

Read it: Otsuka Phase 3b results, Jun 2026 | FDA priority-review acceptance, Jan 2026

The one-scroll summary

A modest but real research week. The freshest item is a large UK twin study reframing ADHD, autism, and learning differences as one heritable “neurodevelopmental spectrum,” alongside a newly publicized psychedelics review urging caution. It’s rounded out with substantive women and girls findings on multimorbidity, perimenopause, and pregnancy. The big change to watch is the FDA’s July 24 centanafadine decision.

Know someone who needs this? Forward it.

Share

Keep reading

👉 Browse Every Briefing

Further reading:
ADHD & Sleep | Research Briefing

Connect:
About Me | Bluesky | Facebook | Instagram | Pinterest | YouTube

The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.

The theme this week: origins, and a countdown. Several of the strongest new findings dig into where ADHD comes from, genes switched on in toddlerhood, and the back-and-forth between babies and parents, while the clinical world watches the clock on a novel drug awaiting an FDA verdict.

Genes that shape how busy a toddler is overlap with ADHD genes

An international team led by the University of Surrey scanned the DNA of nearly 80,000 infants and found that the genetic “dial” turning up a toddler’s activity level, centered on a gene called RHEBL1 that is active in the brain’s cortex, draws on many of the same variants tied to ADHD years later.

• Worth knowing because: Think of it as spotting the fingerprints of ADHD in behavior that shows up long before anyone would diagnose it, which could eventually help flag risk far earlier.

Primary: Nature Human Behaviour
Press Release: University of Surrey

A new non-stimulant shows added benefits, though the data is early and company-run

Centanafadine, which nudges three brain chemicals (dopamine, norepinephrine, serotonin) rather than the usual two, was linked to gains in adults’ executive function and emotional regulation, not just the core attention symptoms. Hold it loosely: these are post-hoc, exploratory analyses presented at a conference and announced by the maker, Otsuka, and they have not yet been peer-reviewed.

• Worth knowing because: Centanafadine is a low-abuse-potential non-stimulant, and the FDA is expected to rule around July 24.

Primary: Otsuka release, May 28, 2026 (post-hoc, exploratory, not peer-reviewed). Plain-English read: Psychiatric Times.

How fast a mom answers a baby’s babble may hint at later ADHD

Researchers replayed archived audio-video of 12-month-olds and their mothers and found that when a mother was slower to vocally “answer” her baby’s babbles, that child was more likely to be diagnosed with ADHD or a disruptive behavior disorder by age 7.

• Worth knowing because: The takeaway is not blame. It’s that the split-second rhythm of parent-child “conversation” could become an objective, very early screening signal.

Primary: PLOS ONE, July 1, 2026
Press Release: University of Glasgow

A large sibling study finds Tylenol in pregnancy does not raise ADHD risk

Using Hong Kong data that compared siblings, a design that cancels out shared family and genetic factors, researchers found no increased ADHD or autism risk from prenatal acetaminophen.

• Worth knowing because: Earlier alarms likely reflected the mother’s underlying health rather than the medication itself, a reassuring and timely counterweight to a debate that keeps resurfacing.

Primary: JAMA Internal Medicine, June 29, 2026
Plain-English read: HKUMed.

Microdosing psychedelics for ADHD: hype outruns the evidence

A Wroclaw Medical University review found only five qualifying studies and concluded the science is not there yet, promising as a research direction but not ready for the clinic. (Originally published in April and resurfaced in the press this week.)

• Worth knowing: given how much anecdotal enthusiasm circulates online.

Primary: Int. J. Mol. Sci., April 12, 2026
Plain-English read: Wroclaw Medical University

On the horizon

The FDA’s expected decision on centanafadine around July 24. If approved, it would add a genuinely new non-stimulant option to the ADHD toolkit, and next week’s coverage will likely start previewing what that means for patients.

A note on scope

New peer-reviewed ADHD research this specific week was moderate rather than blockbuster. The items above are the most substantive and best-sourced, with each linked to its primary journal or institutional release and the plain-English coverage offered as a secondary read. Two carry caveats: the centanafadine data is a manufacturer’s conference presentation, not yet peer-reviewed, and the microdosing review recirculated in the press this week but actually published in April.

Keep reading

• Browse every briefing

Further Reading:
ADHD & Sleep | Research Briefing

Connect:
About Me | Bluesky | Facebook | Instagram | Pinterest | YouTube

The research referenced in this article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis or treatment.